Food and Drug Reform Act

Food and Drug Reform Act - Amends the Federal Food, Drug, and Cosmetic Act to reduce the reporting requirements on applications for new drugs and new animal drugs to require only a summary, not a full report, on each investigation, and to prohibit any required resubmission of certain reports with an application if such a report was submitted within four years of the date of the application.

Requires the Secretary of Health, Education, and Welfare, prior to issuing, amending or repealing any regulation under such Act, to issue a comprehensive economic impact statement addressing specified questions. Requires semiannual reports to Congress on the status of each new drug and new animal drug application which has not been approved or disapproved 30 days before the submission of the report.

Establishes drug advisory committees which shall promptly review an application and submit recommendations to the Secretary within 90 days. Grants applicants the right to a mandatory review within 30 days after receiving an adverse recommendation.

Requires the Secretary to publish the clinical and preclinical summaries of new drugs and new animal drugs whose applications are approved.

Exempts small businesses from the requirement of preclinical test reports on drugs used solely in investigational research, if such research will be conducted by experts from a public or other nonprofit school of medicine, dentistry, or veterinary medicine.

Requires Congressional review of the administration of such Act by the Department of Health, Education, and Welfare in 1982 and every six years thereafter.

Directs the Secretary to establish within the Department an office to provide compliance assistance to small manufacturers of new drugs and new animal drugs.

Extends the patent term for new drugs or new animal drugs approved by the Secretary on or after July 1, 1977 to either: (1) 17 years after approval; or (2) 27 years after patent issuance, whichever starting date is earlier.